

**ENVIRONMENTAL PROTECTION
AGENCY**

June 4, 2010, make the following
correction:

40 CFR Part 52**§52.420 [Corrected]**

[EPA-R03-OAR-2010-0039; FRL-9158-3]

**Approval and Promulgation of Air
Quality Implementation Plans;
Delaware; Control of Nitrogen Oxide
Emissions From Industrial Boilers and
Process Heaters at Petroleum
Refineries**

On page 31712 in §52.420, the table
titled EPA-APPROVED REGULATIONS IN
THE DELAWARE SIP should appear as
follows:

Correction

In rule document 2010–13377
beginning on page 31711 in the issue of

EPA-APPROVED REGULATIONS IN THE DELAWARE SIP

State citation	Title/subject	State effective date	EPA approval date	Additional explanation
*	*	*	*	*
Regulation 1142—Specific Emission Control Requirements (Formerly Regulation No. 42)				
*	*	*	*	*
Section 2.0	Specific Emission Control Requirements.	11/11/09	6/4/10 [Insert page number where the document begins].	Emission limitations for any industrial boiler or process heater with a maximum heat input capacity of equal to or greater than 200 mmBTU/hr.
*	*	*	*	*

[FR Doc. C1–2010–13377 Filed 6–9–10; 8:45 am]

BILLING CODE 1505–01–D

**DEPARTMENT OF HEALTH AND
HUMAN SERVICES****Centers for Medicare & Medicaid
Services****42 CFR Parts 417, 422, 423, and 480**

[CMS–4085–CN]

RIN 0938–AP77

**Medicare Program; Policy and
Technical Changes to the Medicare
Advantage and the Medicare
Prescription Drug Benefit Programs;
Corrections**

AGENCY: Centers for Medicare &
Medicaid Services (CMS), HHS.

ACTION: Correction of final rule.

SUMMARY: This document corrects
technical and typographical errors in
the final rule that appeared in the April
15, 2010 **Federal Register** entitled
“Medicare Program; Policy and
Technical Changes to the Medicare
Advantage and the Medicare
Prescription Drug Benefit Programs.”

DATES: *Effective Date:* This correction
notice is effective June 7, 2010.

FOR FURTHER INFORMATION CONTACT:

Alissa Deboy, (410) 786–6041.

SUPPLEMENTARY INFORMATION:**I. Background**

In the final rule entitled “Medicare
Program; Policy and Technical Changes
to the Medicare Advantage and the
Medicare Prescription Drug Benefit
Programs” which appeared in the April
15, 2010 **Federal Register** (FR Doc.
2010–7966, (75 FR 19678)), there were
technical and typographical errors that
are identified and corrected in the
Correction of Errors section below. The
provisions in this correction notice are
effective as if they had been included in
the document that appeared in the April
15, 2010 **Federal Register**. Accordingly,
the corrections are effective June 7,
2010.

II. Summary of Errors

On page 19752, in our preamble
discussion regarding risk adjustment
data validation (RADV) appeals and the
addition of Medicare Advantage (MA)
organization RADV—dispute and appeal
procedures we made typographical
errors in two regulatory citations and we
correct these errors in section IV.A.1. of

this correction notice. In addition, on
page 19809 in the regulations text for
the RADV provisions, we inadvertently
designated two paragraphs as
§ 422.311(c)(iii)(C). We are correcting
this error in section IV.B.1. of this
correction notice.

In our preamble discussion of criteria
and procedures for identifying
“protected classes” of drugs within
which all covered Part D drugs must be
included in Part D formularies (75 FR
19767), we indicated that we would not
finalize in regulations (§ 423.100) our
proposed definitions used to interpret
the section 176 of Medicare
Improvements for Patients and
Providers Act of 2008 (MIPPA) criteria
(that is, the definitions for the terms,
“drug category or class,” “major or life
threatening clinical consequences,”
“restricted access,” and “significant need
for access to multiple drugs”). However,
we indicated that we would finalize our
proposed regulations text regarding the
exceptions criteria (§ 423.120(b)(2)(iv)).
Therefore, in section IV.B.3. and 4. of
this correction notice, we correct these
errors by removing the proposed
definitions inadvertently published for
§ 423.100 and adding the exceptions
criteria that were inadvertently omitted
from § 423.120(b).

On page 19812, we presented our regulatory changes to § 422.566 and § 422.568 regarding organization determinations. We made errors in the amendatory statements for the regulations text of these sections regarding the redesignation of paragraphs. We are also correcting a technical error in § 422.566(c)(2)(i) (changing “A” to “The”) to ensure consistency between paragraphs (c)(1)(i) and (c)(2)(i). In section IV.B.2 of this correction notice, we correct these errors.

On page 19822, we presented our regulatory changes to § 423.551 regarding changes in ownership during a PDP term of contract. In presenting these regulatory changes, we indicated that we were adding a new paragraph (g) instead of indicating that we were revising the existing paragraph (g). In section IV.B.5. of this correction notice, we correct this error.

In our acronyms list and in the preamble discussion and regulations text regarding medication therapy management programs under Part D, we erroneously used the term “comprehensive medical review” instead of “comprehensive medication review.” Therefore, in section IV. A.2, 4. and 5. and B.5. of this correction notice we are correcting these errors. In addition, we inadvertently listed the acronym for comprehensive medical reviews (CMR) twice. We also correct the erroneous listing of the acronym in section IV.A.1. of this correction notice.

III. Waiver of Proposed Rulemaking and Waiver of the Delay in Effective Date

We ordinarily publish a notice of proposed rulemaking in the **Federal Register** to provide a period for public comment before the provisions of a rule take effect in accordance with section 553(b) of the Administrative Procedure Act (APA) (5 U.S.C. 553(b)). In addition, section 553(d) of the APA (5 U.S.C. 553(b)) ordinarily requires a 30-day delay in effect date of final rules after the date of their publication in the **Federal Register**. However, we can waive both the notice and comment procedure and the 30-day delay in effective date if the Secretary finds, for good cause, that the notice and comment process is impracticable, unnecessary, or contrary to the public interest, and incorporates a statement of the finding and the reasons therefore in the notice.

This document merely corrects typographical and technical errors made in the Policy and Technical Changes to the Medicare Advantage and the Medicare Prescription Drug Benefit

Programs final rule (FR. Doc. 2010–7966) which appeared in the April 15, 2010 **Federal Register** and will be effective on June 7, 2010. The provisions of the final rule have been subjected previously to notice and comment procedures. The corrections contained in this document are consistent with and do not make substantive changes to, the policies adopted in the final rule. Therefore, we find it unnecessary to undertake further notice and comment procedures with respect to this correction notice. We also believe it is in the public interest to waive notice and comment procedures and the 30-day delay in effective date for this notice. This correction notice is intended to ensure that the final rule accurately describes the policies being adopted in the final rule, and that correct information is made available to the public prior to June 7, 2010, the date on which the final rule becomes effective.

For the reasons stated above, we find that both notice and comment and the 30-day delay in effective date for this correction notice are unnecessary, and that it is in the public interest to make this notice effective in conjunction with the final rule to which the corrections apply. Therefore, we find there is good cause to waive notice and comment procedures and the 30-day delay in effective date for this correction notice.

IV. Correction of Errors

In FR Doc. 2010–7966 of April 15, 2010, (75 FR 19678), make the following corrections:

A. Correction of Errors in the Preamble

1. On page 19679, third column, second line from the bottom, the acronym and term “CMR Comprehensive Medical Review” is corrected by deleting the acronym and term.
2. On page 19680, first column, top of the page, line 1, the term for the acronym CMR, “Comprehensive Medical Review” is corrected to read “Comprehensive Medication Review”.
3. On page 19752—
 - a. In the first column, last paragraph, line 1, the citation § 422.311(c)(2)(v) is corrected to read “§ 422.311(c)(2)(ix)”.
 - b. In the second column, first partial paragraph, line 5, the citation § 422.311(c)(2)(vi) is corrected to read “§ 422.311(c)(2)(x)”.
4. On page 19773, in the second column, first full paragraph, line 5, the term “comprehensive medical review” is corrected to read “comprehensive medication review”.
5. On page 19793, first column—

- a. Second full paragraph, lines 8 and 9, the term “comprehensive medical review” is corrected to read “comprehensive medication review”.

- b. Last paragraph—
 - (1) Lines 4 and 5, the term “medical reviews” is corrected to read “medication reviews”.
 - (2) Line 6, the term “medical review” is corrected to read “medication review”.

B. Correction of Errors in the Regulations Text

1. On page 19809, in the first column, second full paragraph, line 1, the paragraph designation “(C)” is corrected to read “(D)”.

2. On page 19812, in the second column—

- a. In the first full paragraph, in the amendatory statement for § 422.566 (statement number 37)—

- (1) Lines 4 and 5 (amendatory instruction C), the sentence “Redesignating paragraph (b)(5) as (b)(6)” is corrected by removing the amendatory instruction.

- (2) Line 7 (amendatory instruction D), the sentence “Adding a new paragraph (b)(5) is corrected by removing the amendatory instruction.

- (3) Line 8 (amendatory statement E), the phrase “In paragraphs (c)(1)(i), and (c)(2)(i)” is corrected to read “In paragraph (c)(1)(i)”.

- (4) Line 14 (after amendatory statement E and before the phrase “The revision and addition”), the paragraph is corrected by adding the following sentence “F. In paragraph (c)(2)(i), the phrase ‘An enrollee (including his or her authorized representative)’; is removed and the phrase ‘The enrollee (including his or her representative);’ is added in its place.”

- b. In the fourth full paragraph, the paragraph “(5) Reduction of a previously authorized course of treatment if the enrollee believes that continuation of the course of treatment is medically necessary.” is corrected by removing the paragraph.

- c. In the fifth full paragraph, in the amendatory statement for § 422.568 (statement number 38), lines 2 through 7, the sentence beginning with the phrase “A. Redesignating paragraphs (a)” through the sentence ending with phrase “newly redesignated paragraph (d)” are corrected to read as follows:

- “A. Redesignating paragraphs (c) and (d) as paragraphs (d)(1) and (d)(2), respectively.

- B. Redesignating paragraphs (a) and (b) as (b) and (c).

- C. Adding a new paragraph (a).

- D. Revising newly redesignated paragraph (d).”

3. On page 19816—

a. First and second columns, second paragraph from the bottom of the page through the sixth full paragraph; the paragraph beginning with the phrase “61. Section 423.100” through the paragraph ending with the phrase “on various individuals.” is corrected by deleting these paragraphs.

b. In the third column, second full paragraph, in the amendatory statement for § 423.120 (statement number 64), line 6 (immediately following amendatory statement C), the paragraph is corrected by adding the following amendatory statement “D. Adding a new paragraph (b)(2)(vi).”

4. On page 19817, third column, after the third full paragraph ((b)(1)(ix)) which ends with “* * * *”, the paragraph is corrected by adding the following paragraphs:

“(2) * * *

(vi) Exceptions to paragraph (b)(2)(v) of this section are as follows:

(A) Drug products that are rated as therapeutically equivalent (under the Food and Drug Administration’s most recent publication of “Approved Drug Products with Therapeutic Equivalence Evaluations,” also known as the Orange Book).

(B) Utilization management processes that limit the quantity of drugs due to safety.

(C) Other drugs that CMS specifies through a process that is based upon scientific evidence and medical standards of practice (and, in the case of antiretroviral medications, is consistent with the Department of Health and Human Services Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents) and which permits public notice and comment.

5. On page 19818, second column, fifth paragraph from the bottom (regulations text for § 423.153(d)(1)(vii)(B)), lines 3 and 4, the term “comprehensive medical review” is corrected to read “comprehensive medication review”.

6. On page 19822, in the third column, third paragraph from the bottom of the page, in the amendatory statement for § 423.551 (statement number 84), line 2, the phrase “adding a new paragraph (g)” is corrected to read “revising paragraph (g).”

Authority: Catalog of Federal Domestic Assistance Program No. 93.773, Medicare—Hospital Insurance; and Program No. 93.774, Medicare—Supplementary Medical Insurance Program.

Dated: June 4, 2010.

Dawn L. Smalls,

Executive Secretary to the Department.

[FR Doc. 2010–13923 Filed 6–7–10; 4:15 pm]

BILLING CODE 4120–01–P

GENERAL SERVICES ADMINISTRATION

48 CFR Part 505

[GSAR Amendment 2010–02; GSAR Case 2008–G503 (Change 45) Docket 2008–0007; Sequence 11]

RIN 3090–AI71

General Services Administration Acquisition Regulation; GSAR Case 2008–G503, Rewrite of GSAR Part 505, Publicizing Contract Actions

AGENCIES: Office of Acquisition Policy, General Services Administration (GSA).

ACTION: Final rule.

SUMMARY: The General Services Administration (GSA) is issuing a final rule amending GSA Acquisition Regulation (GSAR) which provides requirements for publicizing contract actions.

DATES: *Effective Date:* June 10, 2010.

FOR FURTHER INFORMATION CONTACT: For clarification of content, contact Beverly Cromer, Procurement Analyst, at (202) 501–1448. For information pertaining to status or publication schedules, contact the Regulatory Secretariat at (202) 501–4755. Please cite Amendment 2010–02, GSAR Case 2008–G503 (Change 45).

SUPPLEMENTARY INFORMATION:

A. Background

The GSA published a proposed rule, with request for comments, in the **Federal Register** at 73 FR 53404 on September 16, 2008. No comments were received in response to the proposed rule. This rule covers the GSAR portion of part 505. Currently, subparts 505.1, 505.2, and 505.5 are identified as “shaded” for regulatory coverage; however, the agency has deemed, these subparts as non-regulatory because the coverage addresses internal agency acquisition policy. These subparts have been revised and are moved to the non-regulatory portion of the GSA Acquisition Manual (GSAM).

This is not a significant regulatory action and, therefore, was not subject to review under Section 6(b) of Executive Order 12866, Regulatory Planning and Review, dated September 30, 1993. This rule is not a major rule under 5 U.S.C. 804.

B. Regulatory Flexibility Act

The General Services Administration certifies that this final rule will not have a significant economic impact on a substantial number of small entities within the meaning of the Regulatory Flexibility Act, 5 U.S.C. 601, *et seq.*, because the revisions are not considered substantive.

C. Paperwork Reduction Act

The Paperwork Reduction Act does not apply because the changes to the GSAR do not impose recordkeeping or information collection requirements, or otherwise collect information from offerors, contractors, or members of the public that require approval of the Office of Management and Budget under 44 U.S.C. chapter 35, *et seq.*

List of Subjects in 48 CFR Part 505

Government procurement.

Dated: May 17, 2010.

Rodney P. Lantier,

Acting Senior Procurement Executive, Office of Acquisition Policy, General Services Administration.

■ Therefore, under the authority of 40 U.S.C. 121(c), GSA removes and reserves 48 CFR part 505.

PART 505 [Removed and Reserved]

[FR Doc. 2010–13902 Filed 6–9–10; 8:45 am]

BILLING CODE 6820–61–S

DEPARTMENT OF TRANSPORTATION

Federal Motor Carrier Safety Administration

49 CFR Parts 390 and 395

Regulatory Guidance Concerning the Preparation of Drivers’ Record of Duty Status To Document Compliance With the Hours-of-Service Requirements

AGENCY: Federal Motor Carrier Safety Administration (FMCSA), DOT.

ACTION: Notice of regulatory guidance.

SUMMARY: The FMCSA announces regulatory guidance concerning the requirement for interstate commercial motor vehicle (CMV) drivers to prepare, in duplicate, a record of duty status for each 24-hour period. FMCSA has determined that the current requirement may be satisfied through the preparation of an original handwritten record, and subsequent electronic submission to the motor carrier of a scanned image of the original record; the driver would retain the original while the carrier maintains the electronic scanned electronic image along with any supporting documents.